The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.

Can GLP-1 Meds Harm Your Eyes? By Ernie Mundell HealthDay Reporter MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss ...

Now, diabetes specialists and cardiologists are among the specialists flocking to GLP-1 drugs to manage blood sugar and weight. In many ways, it's easier for physicians to access these drugs.

Are you a print subscriber? Activate your account. By Ad Age Staff - 2 hours 11 min ago By Ad Age and Creativity Staff - 2 hours 28 min ago By Jack Neff - 3 hours 14 min ago 4 hours 25 min ago 6 ...

MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss drugs, but the jury's out on whether the medications caused the eye ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have ... including sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors. Compared to usual care, GLP-1RA use was linked ...

Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist. The Danish pharma ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 ...

Anyone on a GLP-1 inhibitor can tell you downing even one glass of wine can be a challenge, but Kahn says her patients have stopped everything from smoking to compulsive shopping. “It influences ...

Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are ...

Global Partners LP (NYSE:GLP) Q1 2024 Earnings Call Transcript May 8, 2024 Global Partners LP misses on earnings expectations. Reported EPS is $-0.37258 EPS, expectations were $0.1. GLP isn’t ...